Latest News and Press Releases

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling...

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial Lead gene therapy asset, SPVN06, reported to be well-tolerated in first...

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach...

SparingVision appoints Joseph C. Papa as Chairman Former Bausch and Lomb Chairman and CEO joins as non-executive independent Chairman as SparingVision enters the clinic with first gene agnostic lead...

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa SparingVision set to advance into the clinic with breakthrough gene-independent approach...

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases Proceeds to fund first-in-human trials of breakthrough gene therapy...

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases Proceeds to fund first-in-human trials of breakthrough gene therapy...

SparingVision lève 75 millions d'euros pour accélérer le développement de son portefeuille de produits de médecine génomique  en ophtalmologie Cette levée de fonds permettra de financer les premières...

SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and...

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing...